Metamucil Disease Interactions
There are 4 disease interactions with Metamucil (psyllium).
Bulk producing laxatives (applies to Metamucil) intestinal obstruction
Major Potential Hazard, High plausibility. Applicable conditions: Gastrointestinal Obstruction
The use of bulk producing laxatives is contraindicated in patients with intestinal obstruction or fecal impaction. Bulk producing laxatives can exacerbate these conditions.
References
- "Product Information. FiberCon (polycarbophil)." Lederle Laboratories PROD (2001):
- "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals PROD (2001):
- "Product Information. Unifiber (cellulose)." Niche Pharmaceuticals Inc PROD (2001):
Laxatives (applies to Metamucil) inflammatory bowel disease
Major Potential Hazard, Moderate plausibility.
The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.
References
- "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc PROD (2001):
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet PROD
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb PROD
- "Product Information. Neoloid (castor oil)." Paddock Laboratories Inc PROD (2001):
- "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
- "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
Laxatives (applies to Metamucil) intestinal obstruction disorders
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction
The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.
References
- "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc PROD (2001):
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet PROD
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb PROD
- "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet PROD (2001):
- "Product Information. Citrucel (methylcellulose)." SmithKline Beecham PROD (2001):
- "Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc PROD (2001):
- "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
- "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
Bulk producing laxatives (applies to Metamucil) renal dysfunction
Moderate Potential Hazard, High plausibility.
Bulk producing laxatives require the consumption of at least 8 ounces of fluid per each dose. Patients with fluid restriction conditions such as renal dysfunction may benefit more from emollient or stimulant laxatives.
References
- "Product Information. FiberCon (polycarbophil)." Lederle Laboratories PROD (2001):
- "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals PROD (2001):
Metamucil drug interactions
There are 29 drug interactions with Metamucil (psyllium).
Metamucil alcohol/food interactions
There is 1 alcohol/food interaction with Metamucil (psyllium).
More about Metamucil (psyllium)
- Metamucil consumer information
- Check interactions
- Compare alternatives
- Reviews (70)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: laxatives
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.